Ionis’ Tryngolza has received an approval expansion that moves the therapy from rare FCS into severe hypertriglyceridemia—a step that gives Ionis its first widespread cardiometabolic-market foothold. The change reframes Tryngolza as a broader lipid-regimen option for patients with severe hypertriglyceridemia, which carries risk for acute pancreatitis. The expansion also highlights Ionis’ strategy shift: rather than partnering out its assets, the company is leaning into commercialization and building internal revenue pathways around pipeline-to-market progression. For biotech and pharma distribution players, the key near-term question becomes formulary access and prescribing uptake, as payers often decide quickly when a therapy scales beyond a narrow orphan-defined segment.